Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

  • Monteil, Vanessa
  • Kwon, Hyesoo
  • Prado, Patricia
  • Hagelkrüys, Astrid
  • Wimmer, Reiner A.
  • Stahl, Martin
  • Leopoldi, Alexandra
  • Garreta, Elena
  • Hurtado del Pozo, Carmen
  • Prosper, Felipe
  • Romero, Juan Pablo
  • Wirnberger, Gerald
  • Zhang, Haibo
  • Slutsky, Arthur S.
  • Conder, Ryan
  • Montserrat, Núria
  • Mirazimi, Ali
  • Penninger, Josef M.
We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

  • Monteil, Vanessa
  • Kwon, Hyesoo
  • Prado, Patricia
  • Hagelkrüys, Astrid
  • Wimmer, Reiner A.
  • Stahl, Martin
  • Leopoldi, Alexandra
  • Garreta, Elena
  • Hurtado del Pozo, Carmen
  • Prosper, Felipe
  • Romero, Juan Pablo
  • Wirnberger, Gerald
  • Zhang, Haibo
  • Slutsky, Arthur S.
  • Conder, Ryan
  • Montserrat, Núria
  • Mirazimi, Ali
  • Penninger, Josef M.
We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.